Memblaze
100-499人
公司优势
自2011年成立以来，Memblaze 始终坚持自主研发与创新，拥有超过200项闪存技术专利申请，覆盖闪存管理、数据保护、功耗控制、硬件设计等关键技术领域，并在北京、上海及苏州设有研发中心。
Memblaze 的 PBlaze 系列企业级 SSD 已广泛应用于数据库、虚拟化、云计算、大数据、人工智能等领域，为国内领先的互联网企业、云计算厂商、金融机构及三大电信运营商提供稳定可靠的高速闪存存储解决方案，获得广大终端用户的认可与信赖。
同时，Memblaze 积极推动闪存存储生态的发展，紧跟存储行业最新趋势，与 NVMe、PCI-Sig 等国际标准组织深入合作，推动创新技术的市场化应用，使更多企业客户受益于闪存技术带来的价值。
作为一家国产品牌企业，Memblaze 凭借自主创新的技术和稳定可靠的产品，在产业链中发挥重要作用，为企业用户提供高效可靠的新选择。成立十年来，Memblaze 多次被评为国家高新技术企业、中关村前沿技术企业，2021年入选北京“专精特新”中小企业并获“小巨人”称号，2022年获得“北京市市级企业技术中心”资质，PBlaze 系列产品在多家国际权威评测机构的性能测试中始终名列前茅。
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
衡水滨湖新区衡赢脚轮厂成立于2016年4月18日，经营者为张所振，企业地址位于衡水滨湖新区彭杜乡康辛庄村，所属行业为金属制品业，经营范围包括生产、销售脚轮。
衡水卓宁鱼缸制品有限公司成立于2016年，位于河北省衡水市，是一家主要从事专业技术服务业的企业。
安徽众源新能源科技公司诚聘英才
哈尔滨云盛制冷设备销售有限公司成立于2023年5月25日，位于黑龙江省哈尔滨市南岗区王岗镇兴利村图号02-21-17地号1055，所属行业为其他机械设备及电子产品批发，员工规模1-49人，从事批发零售业务。
Visirna was founded in 2022 and has established a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR), a leading global company in small RNA drug development. The company currently has three clinical-stage siRNA drugs targeting cardiovascular and metabolic diseases. In addition, the company possesses independent R&D capabilities and is exploring liver-specific and extrahepatic delivery technologies, as well as broader therapeutic areas.
The company's current pipeline is at the forefront of its competitors, with targets supported by clear genomic and biological evidence, utilizing Arrowhead's validated delivery and chemical modification technology platforms. The company adopts a China-US collaborative clinical development and registration strategy to accelerate product commercialization.
The company's internal R&D capabilities will further enrich the clinical development pipeline in cardiovascular and metabolic diseases, promoting long-term sustainable development, while forming an integrated industry chain from R&D, production to sales through internal and external resources.
Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases.
We are rapidly advancing our clinical pipelines in an array of trials. Currently we have one ongoing Phase 3 registration trial in FCS in China, and will soon join multiple MRCT trials for cardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH.
Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio for cardiovascular and metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases and provide better outcomes for patients.